Cytokinetics, Incorporated

Healthcare · Biotechnology · United States

Last price 63.31 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 8.80B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in h...